Welcome to “Fly Insider,” The Fly’s weekly recap of notable insider stock transactions
NOTABLE INSIDER PURCHASES: Significant insider purchases reported in the prior week from January 29 through February 2 include:
- Director of Vera Therapeutics (VERA) Mah Katabi purchased 161,290 shares of company stock at $31 per share for a total transactiona amount of $4,999,990
- Holder of Tile Shop Holdings (TTSH) Fund1 purchased 67,800 shares of company stock at $6.55 per share for a total transactiona amount of $444,131
- Holder of Skye Bioscience (SKYE) 5AM Partners purchased 5,206,074 shares of company stock at $2.31 per share for a total transactiona amount of $12,026,031
- Director of Perspective Therapeutics (CATX) Robert Williamson purchased 127,206 shares of company stock at 71c per share for a total transactiona amount of $90,711
NOTABLE INSIDER SALES: Significant insider sales reported in the prior week from January 29 through February 2 include:
- Chairman of Olin Corp (OLN) Scott Sutton sold 584,865 shares of company stock at $53.92 per share for a total transaction amount of $31,537,626
- Director of Coinbase Global (COIN) Fred Ehrsam sold 97,836 shares of company stock at $131.57 per share for a total transaction amount of $12,872,204
- Chairman of Netflix ( NFLX) Reed Hastings sold 20,734shares of company stock at $567.16 per share for a total transaction amount of $11,759,468
- VP of KB Home (KBH) Brian Woram sold 93,272 shares of company stock at $60.42 per share for a total transaction amount of $5,635,727
NOTABLE PRICE MOVEMENT AFTER INSIDER TRANSACTION: Shares of Skye Bioscience are up approximately 50% since holder 5AM Partners purchased 5,206,074 shares of company stock at $2.31 per share, while shares of Coinbase fell approximately 12% after Director Fred Ehrsam sold 97,836 shares of company stock at $131.57 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VERA:
- Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Vera Therapeutics director buys $5.0M in common stock
- Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
- Vera Therapeutics Announces $250M Public Stock Offering
- Vera Therapeutics 8.064M share Secondary priced at $31.00
Questions or Comments about the article? Write to editor@tipranks.com